4//SEC Filing
Ajer Jeffrey Robert 4
Accession 0001209191-23-014609
CIK 0001048477other
Filed
Mar 1, 7:00 PM ET
Accepted
Mar 2, 4:09 PM ET
Size
9.3 KB
Accession
0001209191-23-014609
Insider Transaction Report
Form 4
Ajer Jeffrey Robert
SVP, Chief Commercial Of
Transactions
- Award
Common Stock
2023-02-28+7,629→ 79,857 total - Award
Common Stock
2023-02-28+10,380→ 72,228 total - Award
Common Stock
2023-02-28+20,760→ 61,848 total
Footnotes (5)
- [F1]Transaction Date is the date that the Issuer's Board of Directors' Compensation Committee certified that the reporting person earned the Restricted Stock Units (RSUs), which are convertible into shares of the Issuer's Common Stock on a 1:1 basis.
- [F2]Represents the total number of RSUs earned pursuant to a formula based on relative total shareholder return during 2020 through 2022 set forth in the performance-based RSU awards previously granted under the Issuer's 2017 Equity Incentive Plan.
- [F3]Although earned, the RSUs only vest according to the following schedule: vests on March 16, 2023, subject to the reporting person's continued service through that date, subject to earlier vesting upon certain events.
- [F4]Represents the total number of RSUs earned pursuant to a formula based on the number and nature of strategic goals achieved during 2020 through 2022 set forth in the performance-based RSU awards previously granted under the Issuer's 2017 Equity Incentive Plan.
- [F5]Represents the total number of RSUs earned pursuant to a formula based on non-GAAP income over three, one-year periods spanning 2020 through 2022 set forth in the performance-based RSU awards previously granted under the Issuer's 2017 Equity Incentive Plan.
Documents
Issuer
BIOMARIN PHARMACEUTICAL INC
CIK 0001048477
Entity typeother
Related Parties
1- filerCIK 0001557533
Filing Metadata
- Form type
- 4
- Filed
- Mar 1, 7:00 PM ET
- Accepted
- Mar 2, 4:09 PM ET
- Size
- 9.3 KB